The market is growing…

Nearly 12 million adults have been diagnosed with COPD in the U.S.

Asthma affects nearly 334 million people worldwide.

The adoption of O2 therapy is increasing and we saw a need for a change. Something to help these millions of people that assists with controlled flow, efficient dosing, faster response rates with improved durability and reliability. We wanted oxygen therapy to feel as natural as possible and take the guesswork out of the process.

Innovative Solution for Automated Supplemental Oxygen Control

Our device, MoblO2, is for people with advanced lung disease who have been prescribed long-term oxygen therapy (LTOT). It is designed to provides reliable, continuous monitoring and flow variability of the supplemental oxygen supply to assure stable oxygen saturation levels both efficiently and effectively.

To us, it is about restoring hope

Our desire is to restore a person’s hope and spirit while improving the quality of their life for both the patient and their caregiver by providing a smart technology device that takes the fear and anxiety out of supplemental oxygen management.

This product is not currently available for sale in the United States.